205 related articles for article (PubMed ID: 26684327)
1. Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study.
Kourlaba G; Vlachopoulos C; Parissis J; Kanakakis J; Gourzoulidis G; Maniadakis N
BMC Health Serv Res; 2015 Dec; 15():566. PubMed ID: 26684327
[TBL] [Abstract][Full Text] [Related]
2. A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris.
Vellopoulou K; Kourlaba G; Maniadakis N; Vardas P
Int J Cardiol; 2016 May; 211():105-11. PubMed ID: 26994453
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of trimetazidine in the management of chronic stable angina in Greece.
Kourlaba G; Gourzoulidis G; Andrikopoulos G; Tsioufis K; Beletsi A; Maniadakis N
BMC Health Serv Res; 2016 Sep; 16(1):520. PubMed ID: 27678370
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece.
Kourlaba G; Parissis J; Karavidas A; Beletsi A; Milonas C; Branscombe N; Maniadakis N
BMC Health Serv Res; 2014 Dec; 14():631. PubMed ID: 25496716
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Kohn CG; Parker MW; Limone BL; Coleman CI
Am J Cardiol; 2014 Apr; 113(8):1306-11. PubMed ID: 24560062
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective.
Coleman CI; Freemantle N; Kohn CG
BMJ Open; 2015 Nov; 5(11):e008861. PubMed ID: 26546142
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Nguyen E; Coleman CI; Kohn CG; Weeda ER
Int J Cardiol; 2018 Dec; 273():34-38. PubMed ID: 30266352
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
17. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
Storey KM; Wang J; Garberich RF; Bennett NM; Traverse JH; Arndt TL; Schmidt CW; Henry TD
Am J Cardiol; 2020 Aug; 129():1-4. PubMed ID: 32540170
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
20. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
